ACRS - CIK 0001557746
Aclaris Therapeutics, Inc. trades as ACRS. In its fiscal 2025 annual report the company posted revenue of $7.83M, down 58.2% from the prior year and net income of -$64.92M. This page tracks Aclaris Therapeutics, Inc. through 852 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years Aclaris Therapeutics, Inc.'s revenue grew from $1.68M to $7.83M, a compound annual growth rate of 21.2%. Net profit margin expanded from -4071.5% to -829.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-05 |
| Major company event | 8-K | 2026-04-28 |
| Insider trade | 4 | 2026-04-27 |
| SCHEDULE 13G/A | - | 2026-04-27 |
| Annual report to shareholders | ARS | 2026-04-23 |
The largest companies sharing Aclaris Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Aclaris Therapeutics, Inc. reported revenue of $7.83M for fiscal year 2025, a decrease of 58.2% year over year.
In its latest fiscal year Aclaris Therapeutics, Inc. reported a net loss of $64.92M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.